Skip to main content
Akero Therapeutics, Inc. logo

Akero Therapeutics, Inc. — Investor Relations & Filings

Ticker · AKRO ISIN · US00973Y1082 LEI · 549300SI3KG74LBE2955 US Professional, scientific and technical activities
Open in API
Filings indexed 719 across all filing types
Latest filing 2020-06-30 Regulatory Filings
Country US United States of America
Listing US AKRO

About Akero Therapeutics, Inc.

https://akerotx.com/

Akero Therapeutics, Inc. is a clinical-stage company focused on developing and commercializing transformational treatments for patients with serious metabolic diseases characterized by high unmet medical need. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). EFX is being evaluated in multiple clinical trials as a potential foundational therapy for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of liver disease. The program aims to provide a differentiated treatment that addresses the complex pathophysiology of MASH by restoring metabolic balance.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or updates by a company. The text includes disclosures about a press release and a slide presentation related to clinical study results, specifically the Phase 2a BALANCED study for a drug. It does not contain full financial statements or detailed financial analysis typical of annual or quarterly reports. The document primarily announces recent events and provides exhibits (press release and slide presentation) as attachments. Given the nature of Form 8-K filings and the content focusing on event disclosure rather than comprehensive financial reporting, the appropriate classification is Regulatory Filings (RNS). The document length (9611 characters) is sufficient to contain substantive information but it is still an event announcement rather than a full report. Therefore, the classification is RNS with high confidence.
2020-06-30 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content describes the dosing of the first subject in a clinical trial cohort expansion, which is an operational update rather than a financial report or detailed earnings release. It includes forward-looking statements and risk disclosures typical of 8-K filings. There are no financial statements or detailed financial analysis present, so it is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). The document is not a proxy, governance, or management change announcement. Given the nature of the filing and the SEC form type, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-06-17 English
4
Director's Dealing
2020-06-12 English
3
Director's Dealing
2020-06-12 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 9, 2020, reporting the appointment of a new director to the company's Board of Directors. The content focuses on the election of Tomas J. Heyman to the Board, his background, compensation, and indemnification agreement. There are no financial statements or detailed financial performance data. The primary subject is a change in the company's board membership, which fits the category of Board/Management Information (MANG). The document length is about 5987 characters, which is sufficient to contain substantive information about the board change rather than a brief announcement. Therefore, the appropriate classification is MANG with high confidence.
2020-06-10 English
4
Director's Dealing
2020-06-03 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.